1Review1994
Some benefit in clinical studies with patients suffering from mild to moderate degrees of dementia has been demonstrated, but no generally accepted mechanism of action has emerged.
Gouliaev AH, Senning A. · Brain Res Brain Res Rev (1994)
- Comprehensive review of piracetam-class nootropics (1965-1992), including pramiracetam
- Notes modest clinical benefit in mild-to-moderate dementia and a very low toxicity profile
- Emphasizes that no commonly accepted mechanism of action has been established